Sensei Biotherapeutics, Inc (SNSE)

Etorro trading 970x250

About Sensei Biotherapeutics, Inc

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland. Address: 1405 Research Boulevard, Rockville, MD, United States, 20850

Sensei Biotherapeutics, Inc News and around…

Latest news about Sensei Biotherapeutics, Inc (SNSE) common stock and company :

Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
19 Nov, 2021 Yahoo! Finance

BOSTON, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced its participation in a fireside chat during the Piper Sandler 33rd Annual Virtual Healthcare conference being held from November 29 to December 2, 2021. John Celebi, president and chief executive officer and Erin Colgan, senior vice president of finance and administration of Sensei Biot

What Percentage Of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Shares Do Insiders Own?
17 Nov, 2021 Yahoo! Finance

The big shareholder groups in Sensei Biotherapeutics, Inc. ( NASDAQ:SNSE ) have power over the company. Large companies...

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
12 Nov, 2021 Yahoo! Finance

V-domain Ig-containing suppressor of T-cell activation (VISTA) is a novel immune checkpoint protein that has been recognized as an important potential immunotherapeutic target Preclinical data demonstrate that SNS-101 selectivity binds the active form of VISTA induced by the low pH environment of a tumor, which could overcome the challenges of rapid target-mediated drug elimination in the blood IND-enabling studies underway for SNS-101 Company to webcast VISTA science symposium with a leading th

Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights
09 Nov, 2021 Yahoo! Finance

- SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting; abstract available online in the Journal for ImmunoTherapy of Cancer - VISTA science symposium to be webcast Tuesday, November 16 at 4:00 p.m. ET – - Ended third quarter 2021 with cash, cash equivalents and marketable securities of 156.7 million; company reiterated cash ru

Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021
03 Nov, 2021 Yahoo! Finance

BOSTON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, president and chief executive officer, will participate in a fireside chat at the Berenberg virtual U.S. CEO Conference on Tuesday, November 9 at 10:00 a.m. EST. A live audio webcast of the fireside chat can be accessed by visiting the Events & Presentations section of

IWN's Holdings Imply 17% Gain Potential
20 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Value ETF (IWN), we found that the implied analyst target price for the ETF based upon its underlying holdings is $194.03 per unit.

Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
01 Oct, 2021 Yahoo! Finance

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it will present preclinical data for its anti-VISTA (V-domain Ig suppressor of T cell activation) product candidate, SNS-101, during the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held in Washington, D.C. from November 10 - 14, 2021. These data are the f

60 Biggest Movers From Yesterday
25 Aug, 2021 FinancialContent

Gainers Triple-S Management Corporation (NYSE: GTS) shares surged 45.5% to close at $35.20 on Tuesday. GuideWell Mutual Holding ...

Here's Why We're Not Too Worried About Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
17 Aug, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

22 Stocks Moving in Wednesday's Pre-Market Session
11 Aug, 2021 FinancialContent

Gainers CohBar, Inc. (NASDAQ: CWBR) shares rose 78.3% to $2.30 in pre-market trading after the company reported results from the ...

Sensei Biotherapeutics, Inc. (SNSE) Upgraded to Buy: Here's Why
09 Aug, 2021 Yahoo! Finance

Sensei Biotherapeutics, Inc. (SNSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
04 Aug, 2021 FinancialContent
Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
02 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Wednesday
14 Jul, 2021 FinancialContent

Wednesday morning saw 57 companies set new 52-week lows. Noteworthy Points: Campbell Soup (NYSE:CPB) was ...

The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
14 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
13 Jul, 2021 FinancialContent

Before 10 a.m. ET on Tuesday, 48 companies set new 52-week lows. Interesting Highlights: Marqeta ...

Sensei Biotherapeutics is Now Oversold (SNSE)
12 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
09 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
08 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
07 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Friday
02 Jul, 2021 FinancialContent

Before 10 a.m. ET on Friday, 43 companies set new 52-week lows. Points of Interest: Autohome (NYSE:ATHM) ...

Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021
01 Jul, 2021 FinancialContent

Upgrades Citigroup upgraded the previous rating for Thor Industries Inc (NYSE:THO) from Neutral to Buy. For the third quarter, Thor ...

The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
30 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

58 Biggest Movers From Yesterday
30 Jun, 2021 FinancialContent

Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly ...

These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday
29 Jun, 2021 FinancialContent

You might not have heard of them, but one went up big while the other served up a massive disappointment.

35 Stocks Moving In Tuesday's Mid-Day Session
29 Jun, 2021 FinancialContent

Gainers Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares jumped 111.5% to $26.58 after the company announced positive ...

Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021
29 Jun, 2021 FinancialContent

Upgrades For Nutrien Ltd (NYSE:NTR), Susquehanna upgraded the previous rating of Neutral to Positive. In the first ...

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
29 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs
28 Jun, 2021 Yahoo! Finance

- Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs - - Discontinuation of first-generation, single-antigen phage SNS-301 program upon analysis of clinical activity and antigen specific T-cell data - - Cash runway extended into first half of 2024 - - Conference call scheduled for today at 4:30 p.m. ET - BOSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, an immunotherapy company focuse

Sensei Biotherapeutics, Inc (SNSE) is a NASDAQ Common Stock listed in , ,

970x250